Literature DB >> 1696525

Purine nucleoside modulation of functions of human lymphocytes.

T Priebe1, C D Platsoucas, H Seki, F E Fox, J A Nelson.   

Abstract

The accumulation of endogenous substrates in patients with adenosine deaminase deficiency or purine nucleoside phosphorylase deficiency is believed to be responsible for the immunodeficiency observed in these patients. To identify the lymphocyte populations that are most susceptible to these substrates, we investigated the effect of their nucleoside analogs on a number of T and B cell functions of human lymphocytes. We found that tubercidin (Tub), 2-chloro 2'deoxyadenosine (2CldA), 2-fluoro adenine arabinoside-5'phosphate (FaraAMP), and 9-beta-D-arabinosyl guanine (AraGua) inhibited the proliferative responses of human peripheral blood mononuclear cells (PBMC) to polyclonal activators (PHA, OKT3 mab) or to allogeneic PBMC in mixed lymphocyte cultures (MLC). Addition of recombinant IL-2 from the beginning of the culture did not alter the inhibition by Tub of the proliferative responses of PBMC. These purine nucleoside analogs also inhibited the proliferative responses of purified human peripheral blood CD4+ and CD8+ T cells to PHA and of purified B cells to SAC. The concentrations of these nucleosides required to achieve a given degree of inhibition of proliferative responses of T lymphocyte subpopulations or B cells was similar, suggesting that these analogs do not exhibit any selectivity for these purified lymphocyte populations. Tub and FaraAMP, respectively, inhibited and enhanced, at the effector phase, both NK cytotoxicity and specific T cell-mediated cytotoxicity. In contrast to these findings, LAK cytotoxicity at the effector phase was not significantly inhibited by Tub, and was not enhanced by FaraAMP. Both analogs inhibited rIL-2-induced proliferative responses of PBMC, but did not affect the generation of LAK cytotoxicity (induction phase) against the K562 targets when added at the beginning of the culture. This suggests that DNA synthesis is not required for LAK cell induction. Both Tub and FaraAMP inhibited immunoglobulin production (IgG and IgM) by PBMC in the PWM-induced system. These results demonstrate that purine nucleoside analogs significantly inhibited a number of functions of human lymphocytes. Although selectivity for T lymphocyte subpopulations and B cells was not observed, a differential effect of Tub and FaraAMP on LAK cytotoxicity versus NK cytotoxicity and specific T cell cytotoxicity was found.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696525     DOI: 10.1016/0008-8749(90)90208-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.

Authors:  Xiaofeng Sun; Yan Wu; Wenda Gao; Keiichi Enjyoji; Eva Csizmadia; Christa E Müller; Takashi Murakami; Simon C Robson
Journal:  Gastroenterology       Date:  2010-06-25       Impact factor: 22.682

2.  Intracellular disposition of fludarabine triphosphate in human natural killer cells.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-10       Impact factor: 3.333

3.  Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.

Authors:  L E Robertson; A W Denny; Y O Huh; W Plunkett; M J Keating; J A Nelson
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Search for adenosine A2A spare receptors on peripheral human lymphocytes.

Authors:  Laurent Jacquin; Frédéric Franceschi; Youlet By; Josée-Martine Durand-Gorde; Jocelyne Condo; Jean-Claude Deharo; Pierre Michelet; Emmanuel Fenouillet; Régis Guieu; Jean Ruf
Journal:  FEBS Open Bio       Date:  2012-11-17       Impact factor: 2.693

5.  Circulating Human Neonatal Naïve B Cells are Deficient in CD73 Impairing Purine Salvage.

Authors:  Matthew Aaron Pettengill; Ofer Levy
Journal:  Front Immunol       Date:  2016-03-30       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.